

# Edyta Maria Urbanska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4587661/publications.pdf>

Version: 2024-02-01

13  
papers

231  
citations

1478280

6  
h-index

1281743

11  
g-index

14  
all docs

14  
docs citations

14  
times ranked

406  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance. <i>Cancers</i> , 2019, 11, 923.  | 1.7 | 124       |
| 2  | Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat) Tj ETQq0 0 0 rgBT /Overlock 10 Tf adenocarcinoma patient with acquired resistance to crizotinib: a case report. <i>BMC Research Notes</i> , 2013, 6, 489.   | 0.6 | 39        |
| 3  | Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2847.  | 1.8 | 25        |
| 4  | Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation. <i>Lung Cancer</i> , 2017, 113, 14-17.                      | 0.9 | 20        |
| 5  | Intracranial Response of ALK+ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery. <i>Clinical Lung Cancer</i> , 2021, 22, e528-e532. | 1.1 | 8         |
| 6  | Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i> -Mutated Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2022, , .   | 1.5 | 7         |
| 7  | Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer. <i>Clinics and Practice</i> , 2021, 11, 293-302.   | 0.6 | 3         |
| 8  | Treatment Algorithm for Advanced ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e156-e157.  | 0.5 | 2         |
| 9  | P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT. <i>Journal of Thoracic Oncology</i> , 2018, 13, S946.  | 0.5 | 1         |
| 10 | P46.03 Targeting ROS1 Gene Rearrangement by Crizotinib as Neoadjuvant Treatment Before Definitive Radiotherapy in Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, S1094.   | 0.5 | 1         |
| 11 | P46.02 Impact of Real-World DNA- and RNA-Based Rebiopsy Testing in EGFR-Mutated NSCLC Progressing on Osimertinib. <i>Journal of Thoracic Oncology</i> , 2021, 16, S1093-S1094.   | 0.5 | 1         |
| 12 | P3.01-007 Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2203.   | 0.5 | 0         |
| 13 | P10.06 Affiliation to the Labour Market in Denmark for Patients Under 60 Years of Age After Diagnosis and Treatment for ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, S1000-S1001.   | 0.5 | 0         |